Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.
about
From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertensionSaudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertensionValidation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials.Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertensionSex and menopause differences in response to tadalafil: 6-minute walk distance and time to clinical worsening.Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients.Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists.A Contemporary Approach to Pulmonary Arterial Hypertension.Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.Macitentan in pulmonary arterial hypertension: The SERAPHIN trialIloprost in pulmonary hypertension.Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size.Symptom Prevalence, Symptom Severity, and Health-Related Quality of Life Among Young, Middle, and Older Adults With Pulmonary Arterial Hypertension.
P2860
Q33806102-D0D19F3A-C1F0-4937-868B-A9E963CDC011Q33965859-5600B743-2995-440D-85B5-9497DF7370E6Q34541733-C7CE9500-5F7F-4F8B-8F3A-5A0523095D52Q36016546-2F878258-3220-43B3-A63B-4D8BF27B23FEQ36352106-3CE9D548-4C36-4A2D-B084-F039D6BE564EQ37367961-973E1D7F-61B0-46F0-BA4B-18EF780EC7B6Q38233856-A51FC48E-A8AE-4684-A750-B7919ACFFC5EQ38542993-2D0422EC-6D2E-4088-8BE1-A033014F6B8DQ38834511-390FCEFC-88AE-467B-9BDD-470E40A693F2Q38896631-3E3FF69B-8D1E-4EB4-8370-811706891054Q41773926-75BCBBB6-9D68-412D-9354-44EE2A6BF107Q43061658-803D19E4-98A9-4F22-B587-7F920353A3A1Q44473667-25C2074A-559F-4E33-88DF-7AE86CE7479FQ47579257-2A84574F-B40F-455D-B40A-D55A77549DA3Q48063470-7DF1CFCC-20DD-4C39-BB05-AC172618F86F
P2860
Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Surrogate end points in pulmon ...... ssing the response to therapy.
@ast
Surrogate end points in pulmon ...... ssing the response to therapy.
@en
type
label
Surrogate end points in pulmon ...... ssing the response to therapy.
@ast
Surrogate end points in pulmon ...... ssing the response to therapy.
@en
prefLabel
Surrogate end points in pulmon ...... ssing the response to therapy.
@ast
Surrogate end points in pulmon ...... ssing the response to therapy.
@en
P2860
P1476
Surrogate end points in pulmon ...... ssing the response to therapy.
@en
P2093
Jennifer L Snow
Steven M Kawut
P2860
P304
75-89, viii
P356
10.1016/J.CCM.2006.11.005
P577
2007-03-01T00:00:00Z